---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-037318"
form_type: "8-K"
ticker: "DERM"
cik: "0001867066"
company_name: "Journey Medical Corp"
filed_at: "2024-03-21T23:59:59+00:00"
generated_at: "2026-06-04T10:28:29.173710+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Journey Medical reports FY2023 revenue $79.2M (+7% YoY); net loss narrows to $3.9M from $29.6M

## Summary
- Total revenues $79.2M vs $73.7M in 2022; growth driven by $19.0M Maruho licensing revenue.
- Net product revenues fell 16% to $59.7M due to generic competition and Ximino discontinuation.
- Net loss improved to $3.9M ($0.21 loss per share) from $29.6M ($1.69 loss per share) in 2022.
- Adjusted EBITDA turned positive to $15.6M ($0.85 basic EPS) from negative $7.3M in 2022.
- NDA for rosacea candidate DFD-29 accepted by FDA; PDUFA goal date set for November 4, 2024.

## SEC filing metadata
- accession: 0001104659-24-037318
- form_type: 8-K
- ticker: DERM
- cik: 0001867066
- company_name: Journey Medical Corp
- filed_at: 2024-03-21T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867066/000110465924037318/0001104659-24-037318-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867066/000110465924037318/tm249442d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-037318
- JSON: https://secwatch.observer/filing/0001104659-24-037318.json
- Plain text: https://secwatch.observer/filing/0001104659-24-037318.txt

## Key facts
- Earnings Releases
  Journey Medical Corp reported the full year ended December 31, 2023 results: revenue $79.2 million, net income $(3.9) million, EPS $(0.21) per share basic and diluted.
  - Period: the full year ended December 31, 2023
  - Revenue: $79.2 million
  - Net income: $(3.9) million
  - EPS: $(0.21) per share basic and diluted
  - Result: reported results
  source text: EXHIBIT 99.1 Exhibit 99.1 Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights Company generated total revenues of $79.2 million for the full year ended December 31, 2023, a 7% increase from the $73.7 million reported in 2022 Achieved $15.6 million in operating cost savings in 2023, ahead of initial
  evidence_url: https://www.sec.gov/Archives/edgar/data/1867066/000110465924037318/0001104659-24-037318-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.